Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Carmen Pingarrón Santofímia, Pilar Lafuente González, María del Carmen Guitiérrez Vélez, Virginia Calvente Aguilar, Silvia Poyo Torcal, Pablo Terol Sánchez & Santiago Palacios. (2022) Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up. Gynecological Endocrinology 38:7, pages 577-582.
Read now
Read now
Carmen Pingarrón, Pilar Lafuente, Silvia Poyo Torcal, Helena López Verdú, María Sol Martínez García & Santiago Palacios. (2022) Vaginal health, endometrial thickness and changes in bone markers in postmenopausal women after 6 months of treatment with ospemifene in real clinical practice. Gynecological Endocrinology 38:1, pages 78-82.
Read now
Read now
Lino Del Pup & Rafael Sánchez-Borrego. (2020) Ospemifene efficacy and safety data in women with vulvovaginal atrophy. Gynecological Endocrinology 36:7, pages 569-577.
Read now
Read now
David F. Archer, James A. Simon, David J. Portman, Steven R. Goldstein & Irwin Goldstein. (2019) Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. Expert Review of Endocrinology & Metabolism 14:5, pages 301-314.
Read now
Read now
T. J. de Villiers, C. Altomare, M. Particco & M. Gambacciani. (2019) Effects of ospemifene on bone in postmenopausal women. Climacteric 22:5, pages 442-447.
Read now
Read now
Chiara Bondi, Simone Ferrero, Carolina Scala, Emanuela Tafi, Annalisa Racca, Pier Luigi Venturini & Umberto Leone Roberti Maggiore. (2016) Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause. Expert Opinion on Drug Metabolism & Toxicology 12:10, pages 1233-1246.
Read now
Read now
JoAnn V Pinkerton & Risa Kagan. (2015) Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opinion on Pharmacotherapy 16:17, pages 2703-2714.
Read now
Read now
Gregory T Wurz, Chiao-Jung Kao & Michael W DeGregorio. (2014) Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clinical Interventions in Aging 9, pages 1939-1950.
Read now
Read now
Lin H Soe, Gregory T Wurz, Chiao-Jung Kao & Michael W DeGregorio. (2013) Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. International Journal of Women's Health 5, pages 605-611.
Read now
Read now
Jamie L McCall & Michael W DeGregorio. (2010) Pharmacologic evaluation of ospemifene. Expert Opinion on Drug Metabolism & Toxicology 6:6, pages 773-779.
Read now
Read now
Luigi Gennari, Daniela Merlotti, Fabrizio Valleggi & Ranuccio Nuti. (2009) Ospemifene use in postmenopausal women. Expert Opinion on Investigational Drugs 18:6, pages 839-849.
Read now
Read now
A. Nath & R. Sitruk-Ware. (2009) Pharmacology and clinical applications of selective estrogen receptor modulators. Climacteric 12:3, pages 188-205.
Read now
Read now
Pernille Ravn, Therese F. Nielsen & Claus Christiansen. (2006) What can be learned from the levormeloxifene experience?. Acta Obstetricia et Gynecologica Scandinavica 85:2, pages 135-142.
Read now
Read now
Ann Honebrink. (2005) Treatment of menopausal symptoms post-Women’s Health Initiative: refinement of existing treatments and development of new therapies. Expert Opinion on Emerging Drugs 10:3, pages 619-641.
Read now
Read now
Articles from other publishers (44)
Silvia Maffei & Letizia Guiducci. (2022) Effect of Ospemifene on Densitometric and Plasma Bone Metabolism Biomarkers in Postmenopausal Women Reporting Vulvar and Vaginal Atrophy (VVA). Journal of Clinical Medicine 11:21, pages 6316.
Crossref
Crossref
Andrey S. Selyunin, Karinel Nieves-Merced, Danyang Li, Stanton F. McHardy & Somshuvra Mukhopadhyay. (2021) Tamoxifen Derivatives Alter Retromer-Dependent Endosomal Tubulation and Sorting to Block Retrograde Trafficking of Shiga Toxins. Toxins 13:6, pages 424.
Crossref
Crossref
Gloria Bachmann. (2018) Menopausal urogenital changes: welcome expansion of management options over the past 25 years. Menopause 25:5, pages 471-475.
Crossref
Crossref
James A. SimonCorrado AltomareSusannah CortWei JiangJoAnn V. Pinkerton. (2018) Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials. Journal of Women's Health 27:1, pages 14-23.
Crossref
Crossref
David F. Archer, Corrado Altomare, Wei Jiang & Susannah Cort. (2017) Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Menopause 24:10, pages 1167-1174.
Crossref
Crossref
Ginger D. Constantine, David F. Archer, Ricki Pollycove, Wei Jiang, Corrado Altomare & JoAnn V. Pinkerton. (2016) Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data. Menopause 23:9, pages 957-964.
Crossref
Crossref
Natalija Eigeliene, Lauri Kangas, Christina Hellmer, Tommi Kauko, Risto ErkkolaPirkko Härkönen. (2016) Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause 23:7, pages 719-730.
Crossref
Crossref
Ginger D. Constantine, Risa Kagan & Paul D. Miller. (2016) Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women. Menopause 23:6, pages 638-644.
Crossref
Crossref
David F. Archer, Bruce R. Carr, JoAnn V. Pinkerton, Hugh S. Taylor & Ginger D. Constantine. (2015) Effects of ospemifene on the female reproductive and urinary tracts. Menopause 22:7, pages 786-796.
Crossref
Crossref
Petra Stute & Martin Birkhäuser. (2015) Selektive Östrogenrezeptormodulatoren (SERM)Selective estrogen receptor modulators (SERM). Gynäkologische Endokrinologie 13:2, pages 126-134.
Crossref
Crossref
Suzanne E. Wardell, Erik R. Nelson & Donald P. McDonnell. (2014) From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). Steroids 90, pages 30-38.
Crossref
Crossref
Michael W. DeGregorio, Robert L. Zerbe & Gregory T. Wurz. (2014) Ospemifene: A first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids 90, pages 82-93.
Crossref
Crossref
Amber N. McLendon, Valerie B. Clinard & C. Brock Woodis. (2014) Ospemifene for the Treatment of Vulvovaginal Atrophy and Dyspareunia in Postmenopausal Women. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:10, pages 1050-1060.
Crossref
Crossref
Scott Evan Eder. (2014) Ospemifene: A Novel Selective Estrogen Receptor Modulator for Treatment of Dyspareunia. Women's Health 10:5, pages 499-503.
Crossref
Crossref
Barry S. Komm & Sebastian Mirkin. (2014) An overview of current and emerging SERMs. The Journal of Steroid Biochemistry and Molecular Biology 143, pages 207-222.
Crossref
Crossref
Kylie N. Barnes, Erica F. Pearce, Abigail M. Yancey & Alicia B. Forinash. (2014) Ospemifene in the Treatment of Vulvovaginal Atrophy. Annals of Pharmacotherapy 48:6, pages 752-757.
Crossref
Crossref
Zain A. Al-Safi & Nanette Santoro. (2014) Menopausal hormone therapy and menopausal symptoms. Fertility and Sterility 101:4, pages 905-915.
Crossref
Crossref
JoAnn V. Pinkerton & Frank Z. Stanczyk. (2014) Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause 21:3, pages 309-319.
Crossref
Crossref
Yuanshan Cui, Huantao Zong, Huilei Yan, Nan Li & Yong Zhang. (2014) The Efficacy and Safety of Ospemifene in Treating Dyspareunia Associated with Postmenopausal Vulvar and Vaginal Atrophy: A Systematic Review and Meta‐Analysis. The Journal of Sexual Medicine 11:2, pages 487-497.
Crossref
Crossref
Lauri Kangas & Mikko Unkila. (2013) Tissue selectivity of ospemifene: Pharmacologic profile and clinical implications. Steroids 78:12-13, pages 1273-1280.
Crossref
Crossref
Terhi Lehtinen, Ari Tolonen, Miia Turpeinen, Jouko Uusitalo, Jouni Vuorinen, Risto Lammintausta, Olavi Pelkonen & Mika Scheinin. (2013) Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. Biopharmaceutics & Drug Disposition 34:7, pages 387-395.
Crossref
Crossref
Shelley Elkinson & Lily P. H. Yang. (2013) Ospemifene: First Global Approval. Drugs 73:6, pages 605-612.
Crossref
Crossref
Gregory T. Wurz, Lin H. Soe & Michael W. DeGregorio. (2013) Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 74:3, pages 220-225.
Crossref
Crossref
Margery L.S. Gass & Sobia Khan. 2013. Osteoporosis. Osteoporosis
1805
1825
.
Barry S. Komm & Arkadi A. Chines. (2012) An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas 71:3, pages 221-226.
Crossref
Crossref
Tayane Muniz FigheraCarolina Aguiar Moreira KulakJaime Kulak Júnior. (2012) Safety, Efficacy and Patient Acceptability of Bazedoxifene Acetate in the Management of Postmenopausal Osteoporosis. Clinical Medicine Insights: Women's Health 5, pages CMWH.S7308.
Crossref
Crossref
Rebekah A. Burich, Neelima Rakesh Mehta, Gregory T. Wurz, Jamie Lee McCall, Brittany E. Greenberg, Katie E. Bell, Stephen M. Griffey & Michael W. DeGregorio. (2012) Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause 19:1, pages 96-103.
Crossref
Crossref
Shayne Cox GadGregory T. Wurz & Michael W. DeGregorio. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
Pooneh Salari Sharif, Mohammad Abdollahi & Bagher Larijani. (2010) Current, new and future treatments of osteoporosis. Rheumatology International 31:3, pages 289-300.
Crossref
Crossref
James H. Pickar, Tanya MacNeil & Kathleen Ohleth. (2010) SERMs: Progress and future perspectives. Maturitas 67:2, pages 129-138.
Crossref
Crossref
Gloria A. Bachmann & Janne O. Komi. (2010) Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women. Menopause 17:3, pages 480-486.
Crossref
Crossref
Jaime Kulak Júnior, Carolina Aguiar Moreira Kulak & Hugh S. Taylor. (2010) SERMs in the prevention and treatment of postmenopausal osteoporosis: an update. Arquivos Brasileiros de Endocrinologia & Metabologia 54:2, pages 200-205.
Crossref
Crossref
E. Michael Lewiecki. (2009) Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis. Journal of Women's Health 18:10, pages 1615-1626.
Crossref
Crossref
Hugh S. Taylor. (2009) Designing the ideal selective estrogen receptor modulator-an achievable goal?. Menopause 16:3, pages 609-615.
Crossref
Crossref
Anu Kallio, Tao Guo, Elisa Lamminen, Jani Seppänen, Lauri Kangas, H. Kalervo Väänänen & Pirkko Härkönen. (2008) Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Molecular and Cellular Endocrinology 289:1-2, pages 38-48.
Crossref
Crossref
Gregory T. Wurz, Utha Hellmann-Blumberg & Michael W. DeGregorio. (2008) Pharmacologic Effects of Ospemifene in Rhesus Macaques: A Pilot Study. Basic & Clinical Pharmacology & Toxicology 102:6, pages 552-558.
Crossref
Crossref
Wendy Shelly, Michael W. Draper, Venkatesh Krishnan, Mayme Wong & Robert B. Jaffe. (2008) Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings. Obstetrical & Gynecological Survey 63:3, pages 163-181.
Crossref
Crossref
H Michael, P L Härkönen, L Kangas, H K Väänänen & T A Hentunen. (2009)
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts
in vitro
. British Journal of Pharmacology 151:3, pages 384-395.
Crossref
Crossref
. 2006. Wiley Handbook of Current and Emerging Drug Therapies. Wiley Handbook of Current and Emerging Drug Therapies.
Janne Komi, Kari S. Lankinen, Michael DeGregorio, Jorma Heikkinen, Seppo Saarikoski, Marjo Tuppurainen, Kaija Halonen, Risto Lammintausta, Kalervo Väänänen, Olavi Ylikorkala & Risto Erkkola. (2006) Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. Journal of Bone and Mineral Metabolism 24:4, pages 314-318.
Crossref
Crossref
Harold A. Harvey, Morihiko Kimura & Alajos Hajba. (2006) Toremifene: An evaluation of its safety profile. The Breast 15:2, pages 142-157.
Crossref
Crossref
Tatjana El??ne Vogelvang, Marius Jan van der Mooren, Velja Mijatovic & Peter Kenemans. (2006) Emerging Selective Estrogen Receptor Modulators. Drugs 66:2, pages 191-221.
Crossref
Crossref
KIM E. NAYLOR & RICHARD EASTELL. 2006. Dynamics of Bone and Cartilage Metabolism. Dynamics of Bone and Cartilage Metabolism
529
540
.
Janne Komi, Kari S. Lankinen, Pirkko H??rk??nen, Michael W. DeGregorio, Sari Voipio, Seppo Kivinen, Risto Tuimala, Tarja Vihtam??ki, Kimmo Vihko, Olavi Ylikorkala & Risto Erkkola. (2005) Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 12:2, pages 202-209.
Crossref
Crossref